PharmaEconomics

Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy

This economic analysis (Markov modelling) of esketamine treatment for depression (TRD) in Italy shows that it may be cost-effective from a societal perspective.

Published

January 20, 2023

Journal

PharmaEconomics

Authors

Rognoni, C., Falivena, C., Costa, F., Armeni, P.